News Archive

All News

All
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025

December 14, 2020
Immunic, Inc. Added to NASDAQ Biotechnology Index
December 2, 2020
BEAT-COV Initiative Requests Support for the Development and Production of New, Innovative COVID-19 Therapies (in German Only)
November 24, 2020
Immunic, Inc. to Participate in Investor Conferences in December
November 17, 2020
Immunic, Inc. Announces Formation of Scientific-Medical Advisory Board
November 10, 2020
Immunic, Inc. to Participate in Investor and Scientific Conferences in November
November 5, 2020
Immunic, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 2, 2020
Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed
October 20, 2020
EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy
September 29, 2020
Immunic, Inc. to Participate in Scientific Conferences in October
September 28, 2020
Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19
September 11, 2020
Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020
September 8, 2020
Immunic, Inc. to Participate in Scientific and Investor Conferences in September
August 20, 2020
Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function
August 10, 2020
Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters’ Option to Purchase Additional Shares
August 4, 2020
Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock
August 3, 2020
Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock
August 2, 2020
Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
July 30, 2020
Immunic, Inc. to Report Second Quarter 2020 Financial Results and Provide Corporate Update
July 29, 2020
Immunic, Inc. to Participate in Investor Conferences in August
July 27, 2020
Immunic, Inc. Announces First Patients Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19
June 22, 2020
Immunic, Inc. to Join Russell 3000® Index
June 15, 2020
Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
June 10, 2020
Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock
June 9, 2020
Immunic, Inc. Announces U.S. Food and Drug Administration Allowance of its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
June 9, 2020
Immunic, Inc. Announces Proposed Public Offering of Common Stock
May 29, 2020
Immunic, Inc. to Participate in Investor and Industry Conferences in June
May 19, 2020
Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020
May 13, 2020
Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients
May 8, 2020
Immunic, Inc. Reports First Quarter 2020 Financial Results and Highlights Recent Activity
April 23, 2020
Immunic, Inc. Announces Pricing of $15 Million Financing
April 21, 2020
Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients
April 17, 2020
Immunic, Inc. Announces Changes to Executive Team
March 16, 2020
Immunic, Inc. Reports Year End 2019 Financial Results and Highlights Recent Achievements
February 11, 2020
Immunic, Inc. to Participate in Scientific and Investor Conferences in February
January 8, 2020
Immunic Exercises its Option for the Exclusive Worldwide License to IMU-856 from Daiichi Sankyo Co., Ltd.
December 4, 2019
Immunic, Inc. to Present Data on IMU-856, for the First Time, at the Crohn’s and Colitis Foundation’s IBD Innovate Conference
November 25, 2019
Immunic, Inc. to Participate in Investor and Scientific Conferences in December
November 19, 2019
Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips
November 7, 2019
Immunic, Inc. Reports Third Quarter 2019 Financial Results and Highlights Recent Activity
November 5, 2019
Immunic, Inc. to Participate in Industry and Investor Conferences in November
October 15, 2019
Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson
October 10, 2019
Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
September 30, 2019
Immunic, Inc. to Participate in Investor and Scientific Conferences in October
September 18, 2019
Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORγt Inverse Agonist
September 11, 2019
Immunic, Inc. to Present Selected Available and Previously Unpublished Data Regarding Lead Program, IMU-838, at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2019
September 5, 2019
Immunic, Inc.’s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range
September 3, 2019
Immunic, Inc. to Participate in Scientific and Investor Conferences in September
August 12, 2019
Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Proof-of-Concept Clinical Trial of IMU-838 for the Treatment of Patients with Primary Sclerosing Cholangitis
August 8, 2019
Immunic, Inc. Reports Second Quarter 2019 Financial Results and Highlights Recent Activity
August 1, 2019
Immunic AG Awarded Research Grant by German Federal Ministry of Education and Research in Support of the InnoMuNiCH Project
July 30, 2019
Immunic, Inc. to Present at the Canaccord Genuity 39th Annual Growth Conference on August 8
July 16, 2019
Immunic, Inc. Appoints Sanjay S. Patel, CFA, as Chief Financial Officer
June 24, 2019
Immunic, Inc. to Present Previously Unpublished Data Regarding Lead Program, IMU-838, at the GI Inflammatory Diseases Summit in Boston
June 21, 2019
Immunic, Inc. Files Financial Statements and Pro Forma Financial Information in Accordance with Previously Completed Stock-for-Stock Exchange Transaction and Provides Corporate Update
June 4, 2019
Immunic, Inc. to Present Newly Available Preclinical Data for IMU-935 in Poster Presentation at the 2nd Conference on Molecular Mechanisms of Inflammation in Trondheim, Norway
May 30, 2019
Immunic, Inc. to Participate in Investor and Scientific Conferences in June
May 9, 2019
Immunic, Inc. to Participate in Upcoming May Conferences
April 29, 2019
Immunic, Inc. Appoints Industry Veteran Tamara A. Seymour as Interim Chief Financial Officer
April 12, 2019
Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases
April 2, 2019
Immunic Therapeutics to Present at the Needham Healthcare Conference on April 10
February 28, 2019
Immunic Therapeutics to Participate in Investor and Medical Conferences in March
February 26, 2019
Immunic Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of IMU-838, an Oral Therapy for Patients with Relapsing-Remitting Multiple Sclerosis
February 6, 2019
Immunic Therapeutics to Present at the BIO CEO & Investor Conference on February 11
January 7, 2019
Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company
November 5, 2018
Immunic enters into a global option and license agreement with Daiichi Sankyo
April 26, 2018
Immunic Reports Start of Enrollment into Clinical Phase 2 Study with IMU-838 in Patients with Ulcerative Colitis
January 11, 2018
FDA approves IND for Immunic Therapeutics’ IMU-838 to proceed with Phase 2 study in ulcerative colitis
December 12, 2017
Immunic Therapeutics Successfully Completes two Phase 1 Studies for IMU-838
September 5, 2017
Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million
February 1, 2017
Immunic Adds EUR 4 Million in Funding to Further Boost Development
January 9, 2017
Immunic strengthens Management Team and Supervisory Board
September 28, 2016
Immunic acquires 4SC’s immunology portfolio
September 27, 2016
Immunic successfully closes 17.5 million Euro Series A financing round

Media and Investor Inquiries

Questions?

Get in touch.

Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09

Send an Email